Radiopharmaceutical developer Neoprobe has completed the sale of its Neoprobe GDS line of gamma detection devices to Devicor Medical Products.
Devicor paid $30 million in cash up front and will pay up to an additional $20 million in royalties based on the business achieving revenue milestones. The completion of the deal marks Neoprobe's evolution into a pure-play radiopharmaceutical company, with its primary focus being on securing regulatory approval for its Lymphoseek radiopharmaceutical.
